Cargando…
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
DPP4 inhibitors (DPP4i) are a class of newly developed antidiabetic drugs which preserve incretin hormones and promote postprandial insulin secretion. Although the cardiovascular effect of DPP4 inhibition has been substantially studied, the exact role of DPP4 in cardiovascular disease especially in...
Autores principales: | Zhong, Jixin, Gong, Quan, Goud, Aditya, Srinivasamaharaj, Srividya, Rajagopalan, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446505/ https://www.ncbi.nlm.nih.gov/pubmed/26075284 http://dx.doi.org/10.1155/2015/606031 |
Ejemplares similares
-
Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease
por: Zhong, Jixin, et al.
Publicado: (2015) -
Dipeptidyl Peptidase 4/Midline‐1 Axis Promotes T Lymphocyte Motility in Atherosclerosis
por: Rao, Xiaoquan, et al.
Publicado: (2023) -
Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
por: Huang, Jie, et al.
Publicado: (2022) -
Dipeptidyl Peptidase 4/Midline‐1 Axis Promotes T Lymphocyte Motility in Atherosclerosis (Adv. Sci. 9/2023)
por: Rao, Xiaoquan, et al.
Publicado: (2023) -
Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud, Aditya, et al.
Publicado: (2015)